The abstract is read at the publisher; the summary is JClub's.
Prescription amphetamine- or methylphenidate-class stimulant treatment during pregnancy among Medicaid-insured individuals with opioid use disorder in Tennessee (2010–2021) is not linked to postpartum overdose or preterm birth.
- Why it matters: Clinicians and Medicaid programs lack safety evidence for continuing stimulants during pregnancy in people with OUD, despite frequent coverage restrictions.
- What they did: In a retrospective cohort of 12,327 pregnancies with OUD, overlap weighting estimated adjusted odds ratios for maternal overdose through 1 year postpartum and neonatal outcomes, with effect modification by buprenorphine.
- The result: Stimulant exposure was not associated with postpartum overdose (aOR, 1.13; 95% CI, 0.61-2.08) or preterm birth (aOR, 1.04; 95% CI, 0.74-1.46), but was linked to higher NICU admission (aOR, 1.58; 95% CI, 1.17-2.14).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.